Adagio Medical Holdings, Inc Common Stock (ADGM)vsEli Lilly and Company (LLY)
ADGM
Adagio Medical Holdings, Inc Common Stock
$0.62
-3.32%
HEALTHCARE · Cap: $16.55M
LLY
Eli Lilly and Company
$1,127.69
+0.93%
HEALTHCARE · Cap: $1.01T
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 52736396% more annual revenue ($72.25B vs $137,000). LLY leads profitability with a 35.0% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 76/100 (B+).
ADGM
Avoid35
out of 100
Grade: F
LLY
Strong Buy76
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 75.6% year-over-year
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Expensive relative to growth rate
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 32.3x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ADGM
The strongest argument for ADGM centers on Revenue Growth, Price/Book. Revenue growth of 75.6% demonstrates continued momentum.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : ADGM
The primary concerns for ADGM are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 4.21 is elevated, increasing financial risk.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, Debt/Equity, P/E Ratio. A P/E of 40.2x leaves little room for execution misses.
Key Dynamics to Monitor
ADGM profiles as a hypergrowth stock while LLY is a growth play — different risk/reward profiles.
LLY carries more volatility with a beta of 0.52 — expect wider price swings.
ADGM is growing revenue faster at 75.6% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 35/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Adagio Medical Holdings, Inc Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
Adagio Medical Holdings, Inc. is an innovative biotechnology firm dedicated to revolutionizing cardiac arrhythmia treatment through its state-of-the-art medical technologies. Utilizing its proprietary platform, the company is at the forefront of developing advanced targeted ablation techniques, addressing unmet needs in the electrophysiology sector. With a robust product pipeline and a seasoned leadership team, Adagio represents a compelling investment opportunity for institutional investors looking to capitalize on growth in the healthcare industry and contribute to improvements in cardiac patient outcomes.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?